DZDan-Xia Zhu

Dan-Xia Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dan-Xia Zhu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Jun Wu

    Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, China

    4 shared publications
  • Jun Wu

    Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China

    3 shared publications
  • Haijiao Yan

    Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, Jiangsu Province, China

    2 shared publications
  • Lu Lu

    Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, Jiangsu Province, China

    2 shared publications
  • Meng-Ying Cui

    Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China

    2 shared publications
  • Qingying Xian

    Department of Oncology The Third Affiliated Hospital The Second People's Hospital of Changzhou Nanjing Medical University Changzhou Jiangsu People's Republic of China

    2 shared publications

Latest Publications

  • Open Access

    The functional roles and therapeutic potential of protein palmitoylation in hepatocellular carcinoma

    by Fang Wei, Zi Qing Zhu, Yu Meng, Yueping Shen, Dan-Xia Zhu, Jun Wu

    Protein palmitoylation is a reversible lipid post-translational modification that influences protein stability, membrane association, and signal transduction. Increasing evidence indicates that dysregulated palmitoylation contributes to tumor development by altering the activity of oncogenes, tumor suppressors, transcription factors, and membrane proteins, as well as by reshaping the tumor microenvironment. However, the biological significance of this modification in hepatocellular carcinoma (HCC) has not yet been fully clarified. This review summarizes current knowledge of palmitoylation-mediated regulation in HCC and evaluates its potential as a therapeutic target. Relevant studies were identified through systematic searches of PubMed and Web of Science using keywords including "protein palmitoylation," "post-translational modification," "hepatocellular carcinoma," and "tumor therapy." Published evidence was analyzed to examine the roles of palmitoylation in HCC cell proliferation, apoptosis, migration, invasion, and associated signaling pathways. Accumulating evidence indicates that protein palmitoylation contributes to hepatocellular carcinoma progression by modulating the activity and localization of key signaling proteins, including Ras, AKT, and YAP. Through these regulatory effects, palmitoylation influences multiple oncogenic pathways such as Wnt/β-catenin, PI3K/AKT/mTOR, Hippo/YAP, and STAT3 signaling. In addition, metabolic regulatory circuits, including the FASN-ZDHHC-20 and PHF2-SREBP1c axes, link lipid metabolism with palmitoylation-dependent signaling in HCC. Emerging pharmacological approaches targeting palmitoylation-related enzymes-such as palmitoyltransferases and depalmitoylases-have shown promising antitumor activity in preclinical studies. Protein palmitoylation represents an important regulatory layer in hepatocellular carcinoma biology, integrating lipid metabolism with oncogenic signaling networks. Therapeutic strategies targeting enzymes that control palmitoylation dynamics may therefore offer new opportunities for HCC treatment. Future investigations should focus on defining the substrate specificity and regulatory mechanisms of individual ZDHHC enzymes, PATs, and depalmitoylases to facilitate the development of more selective therapeutic interventions.

  • Open Access

    Mechanism and role of ferroptosis in the development of gastric cancer

    by Fang Wei, Yu Meng, Dan-Xia Zhu, Jun Wu

    Gastric cancer (GC) represents a prevalent form of malignant neoplasm characterized by elevated incidence and fatality rates, limited early detection capabilities, and unfavorable clinical outcomes. Its occurrence and development involve complex biological processes. As a recently identified form of cellular demise, ferroptosis has been observed across multiple cancer types, garnering significant research interest in contemporary studies. Nevertheless, the precise regulatory networks governing ferroptosis in gastric cancer, along with its functional implications in the initiation and advancement of this malignancy, remain unclear. This study seeks to elucidate the functional significance of ferroptosis in the pathogenesis of GC, systematically review the dysregulated metabolic pathways associated with this cell death process, and elucidate the intricate interactions among ferroptosis-related signaling cascades. These investigations are expected to establish a novel conceptual framework for understanding the molecular pathogenesis of gastric cancer and identifying potential therapeutic interventions. A comprehensive literature search was conducted using PubMed to identify relevant original research articles and review papers examining the molecular mechanisms underlying ferroptosis in gastric carcinoma. The search strategy incorporated the following key terms: “Ferroptosis,” “Ferroptosis and gastric cancer,” “Ferroptosis and GSH,” “Ferroptosis and GPX4,” “Ferroptosis and system Xc-,” “Iron metabolism,” “lipid peroxidation,” “FSP1-CoQ10,” “DHODH-CoQH2,” “GCH1-BH4,” “ferroptosis inducer,” etc. Emerging evidence from contemporary research indicates that targeted ferroptosis represents a novel and potentially efficacious treatment modality for patients with gastric cancer. Along with the identification of precise molecular targets for therapeutic intervention, the metabolic regulatory networks associated with ferroptosis remains an essential area for future research endeavors.


  • Open Access

    NAALADL2-AS2 functions as a competing endogenous RNA to regulate apoptosis and drug resistance in DLBCL

    by Xiaoli Xu, Juan Liu, Cheng Fang, Xu Deng, Danxia Zhu, Jingting Jiang, Changping Wu

    To explore role of NAALADL2-AS2 as ceRNA in DLBCL. Fluorescence in situ hybridization was used to determine location of NAALADL2-AS2 in cells and to verify its expression in DLBCL tissues. The miRNAs interacting with NAALADL2-AS2 and related regulatory genes were identified by small interfering RNA (siRNA) assay, luciferase reporter assay, fluorescent quantitative polymerase chain reaction, western blotting. DLBCL cells transfected with NAALADL2-AS2 siRNA or control siRNA were treated with doxorubicin, rituximab at different concentrations alone or in combination. The growth curves, drug sensitivity changes of cells before and after transfection were detected by MTT assay, ATP-TCA drug sensitivity test. Cell proliferation was detected by BrdU cell proliferation assay, and apoptosis was detected by Annexin V-fluorescein isothiocyanate/propidium iodide staining. The effects and mechanisms of NAALADL2-AS2 on proliferation, apoptosis, drug resistance of DLBCL cells were studied at cellular level. We confirmed expression of NAALADL2-AS2 in both cytoplasm and nuclei of DLBCL cells. Additionally, we observed elevated levels of NAALADL2-AS2 in DLBCL tissues. We discovered that NAALADL2-AS2 functions as ceRNA to inhibit expression of miR-34a, miR-125a, whereas overexpression of NAALADL2-AS2 indirectly upregulates expression of BCL-2. Interfering with NAALADL2-AS2 promoted apoptosis in DLBCL cells, resulting in approximately a 40% increase in sensitivity to doxorubicin and rituximab. In vivo experiments further confirmed that targeting NAALADL2-AS2 effectively suppressed tumor growth, leading to upregulation of miR-34a and miR-125a, downregulation of BCL-2, and enhanced apoptosis in DLBCL cells, which significantly improved their sensitivity to doxorubicin and rituximab by approximately 50%. These results indicate that NAALADL2-AS2/miR-34a, miR-125a/BCL-2 networks hold promise as therapeutic targets for treatment of DLBCL.


  • Open Access

    Role of disulfide death in cancer (Review)

    by Xue Li, Danxia Zhu

    The research field of regulated cell death is growing extensively. Following the recognition of ferroptosis, other unique and distinct forms of regulated cell death, including cuproptosis and disulfide death, have been identified. Disulfide death occurs due to the abnormal accumulation of disulfides within cells in environments lacking glucose, leading to contraction of the actin cytoskeleton, which ultimately triggers various signaling pathways and cell death. The induction of disulfide death in the treatment of cancer may exhibit significant therapeutic potential. Therefore, in the present review, a comprehensive and critical analysis of the current understanding of the molecular mechanisms and regulatory networks of disulfide death is presented. In addition, the potential physiological functions of disulfide death in tumor suppression and immune surveillance as well as its pathological roles and therapeutic potential are described. The core focus areas for future research into this form of cell death are also explored. Given the current lack of extensive clinical findings and well‑defined key concepts, these may be regarded as pivotal points of interest in future studies.


  • Open Access

    Identification of Differentially Expressed Genes Related to the Lipid Metabolism of Esophageal Squamous Cell Carcinoma by Integrated Bioinformatics Analysis

    by Meng-Ying Cui, Xing Yi, Dan-Xia Zhu, Jun Wu

    Purpose: In recent years, lipid metabolism has been reprogrammed to meet the energy and substrate needs of tumorigenesis and development and is a potential new target for cancer treatment. However, the regulatory mechanism of lipid metabolism in esophageal squamous cell carcinoma is not well understood. Methods: We first downloaded the esophageal squamous cell carcinoma (ESCC) gene dataset in the GEO and TCGA databases and analyzed the central differentially expressed genes (DEGs) of ESCC through bioinformatics. Afterwards, the GSEA method was used to analyze the lipid metabolism-related pathway of the central gene in the pathological process of ESCC, and it was determined that the central gene OIP5 was significantly related to the fatty acid metabolism pathway. Our heatmap also revealed that the enrichment of the ACSL family in ESCC tissues was more pronounced than in normal tissues. We hypothesized that OIP5 can regulate the fatty acid metabolism process in ESCC cells and affect the tumorigenic ability of ESCC. Further statistical analysis and experiment were conducted to determine the lipid metabolism-related gene, OIP5′s, expression pattern and clinical significance in ESCC, analyze the effect of OIP5 expression on fatty acid metabolism-related enzymes in ESCC, revealing the specific mechanism of OIP5 that promotes ESCC development. Conclusions: Our study established a correlation between OIP5 expression and clinicopathological factors (tumor size, T stage, N stage, and clinical grade) in esophageal squamous cell carcinoma (p < 0.05). We have also experimentally demonstrated that OIP5 regulates ESCC fatty acid metabolism by influencing the expression of the key enzyme ACSL1 in lipid metabolism.


  • Open Access

    Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review

    by Meng-Ying Cui, Xing Yi, Zhen-Zhen Cao, Dan-Xia Zhu, Jun Wu

    Esophageal cancer is of high importance to occurrence, development, and treatment resistance. As evidenced by recent studies, pathways (e.g., Wnt/β-catenin, AMPK, and Hippo) are critical to the proliferation, differentiation, and self-renewal of esophageal cancer. In addition, the above pathways play a certain role in regulating esophageal cancer and act as potential therapeutic targets. Over the past few years, the function of lipid metabolism in controlling tumor cells and immune cells has aroused extensive attention. It has been reported that there are intricate interactions between lipid metabolism reprogramming between immune and esophageal cancer cells, whereas molecular mechanisms should be studied in depth. Immune cells have been commonly recognized as a vital player in the esophageal cancer microenvironment, having complex crosstalk with cancer cells. It is increasingly evidenced that the function of immune cells in the tumor microenvironment (TME) is significantly correlated with abnormal lipid metabolism. In this review, the latest findings in lipid metabolism reprogramming in TME are summarized, and the above findings are linked to esophageal cancer progression. Aberrant lipid metabolism and associated signaling pathways are likely to serve as a novel strategy to treat esophageal cancer through lipid metabolism reprogramming.


  • Open Access

    The Role of Lipid Metabolism in Gastric Cancer

    by Meng-Ying Cui, Xing Yi, Dan-Xia Zhu, Jun Wu

    Gastric cancer has been one of the most common cancers worldwide with extensive metastasis and high mortality. Chemotherapy has been found as a main treatment for metastatic gastric cancer, whereas drug resistance limits the effectiveness of chemotherapy and leads to treatment failure. Chemotherapy resistance in gastric cancer has a complex and multifactorial mechanism, among which lipid metabolism plays a vital role. Increased synthesis of new lipids or uptake of exogenous lipids can facilitate the rapid growth of cancer cells and tumor formation. Lipids form the structural basis of biofilms while serving as signal molecules and energy sources. It is noteworthy that lipid metabolism is capable of inducing drug resistance in gastric cancer cells by reshaping the tumor micro-environment. In this study, new mechanisms of lipid metabolism in gastric cancer and the metabolic pathways correlated with chemotherapy resistance are reviewed. In particular, we discuss the effects of lipid metabolism on autophagy, biomarkers treatment and drug resistance in gastric cancer from the perspective of lipid metabolism. In brief, new insights can be gained into the development of promising therapies through an in-depth investigation of the mechanism of lipid metabolism reprogramming and resensitization to chemotherapy in gastric cancer cells, and scientific treatment can be provided by applying lipid-key enzyme inhibitors as cancer chemical sensitizers in clinical settings.


  • Open Access

    The Involvement of WDHD1 in the Occurrence of Esophageal Cancer as a Downstream Target of PI3K/AKT Pathway

    by Qingying Xian, Danxia Zhu

    Esophageal cancer is one of the most common malignant tumors in the world, which is characterized by high incidence, strong invasiveness, high mortality, and poor prognosis. At present, the therapies include surgery, endoscopic resection, radiotherapy and chemotherapy, targeted therapy, and immunotherapy. The five-year survival rate of esophageal cancer has not been significantly improved, although the medical level has been continuously improved and the management and application of different therapies have been improved day by day. At present, an abnormal gene expression is still regarded as an important factor in the occurrence and development of esophageal cancer. WD repeat and HMG-box DNA binding protein 1(WDHD1), as a key gene, plays an important role in the occurrence of esophageal cancer. It is known that the protein encoded by WDHD1 is the downstream target of the PI3K/AKT pathway. When PI3Ks is activated by extracellular signals, PI(4,5)P2 on the inner side of the plasma membrane will be converted into PI(3,4,5)P3. Then, PI(3,4,5)P3 can be converted into PI(3,4)P2,PI(4)P and PI(3)P by dephosphorylation of some regulatory factors. PI(3,4,5)P3 recruited AKT to the plasma membrane and combined with its pH domain, resulting in conformational change of AKT. Subsequently, AKT was completely activated by PDK1 and PDK2 and begins to move to the cytoplasm and nucleus. In this process, AKT continuously phosphorylates downstream substrates. WDHD1, as a downstream target of AKT, is also phosphorylated and induces DNA replication. Besides the abnormal regulation of cells by other downstream targets of AKT, it also becomes a potential pathway that may eventually lead to the occurrence of esophageal cancer.


  • Open Access

    m6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the m6A Modification of YAP1

    by Wenjie Zhou, Qingying Xian, Qi Wang, Chen Wu, Haijiao Yan, Xiaodong Li, Lu Lu, Changping Wu, Danxia Zhu, Xiaoli Xu, et al.

    Gastric cancer is the most common gastrointestinal tumor with an increasing incidence. Furthermore, advanced gastric cancer is more common, but the mechanism underlying the proliferation and metastasis of gastric cancer has not been thoroughly explored. N6-methyladenosine (m6A) methyltransferase 3 (METTL3) may be involved in the proliferation and metastasis of gastric cancer. Therefore, Yes-associated protein 1 (YAP1) in the Hippo pathway was selected as the target, and the relationship between METTL3 and the proliferation and metastasis of gastric cancer was proved through a series of experiments. This research showed that the expression of m6A and METTL3 was upregulated in human gastric cancer tissues and gastric cancer cell lines. After lentiviral transfection, METTL3 silencing in AGS (human gastric adenocarcinoma cell line AGS) and MKN-45 (human gastric cancer cell line MKN-45) gastric cancer cell lines directly inhibited the proliferation, aggressiveness, and migration of gastric cancer cells. Mechanically, the inhibition of the YAP1-TEAD signaling pathway by peptide 17 reduces m6A methylation and the total mRNA level of YAP1. It also eliminates the promoting effect of METTL3 on the proliferation and migration of gastric cancer cells. In turn, the overexpression of YAP1 eliminates the inhibitory effect of METTL3 silencing on the proliferation, migration, and invasion of gastric cancer cells. This article proved that m6A methyltransferase METTL3 promoted the proliferation and migration of gastric cancer cells through the m6A modification of YAP1.


  • Open Access

    Aberrant lipid metabolism reprogramming and immune microenvironment for gastric cancer: a literature review

    by Meng-Ying Cui, Xing Yi, Dan-Xia Zhu, Jun Wu

    Objective: We summarize the aberrant lipid metabolism disorders associated with enzyme activity and expression changes and related immune microenvironment for gastric cancer. Background: Gastric cancer is a malignant tumor of the primary digestive system with high incidence, poor prognosis characterized by extensive metastasis and poor effect with radiotherapy and chemotherapy. One of the most important metabolic characteristics of cancer cells is lipid metabolism reprogramming to adapt to the tumor micro-environment. Methods: The focus of research in recent years has also been on lipid metabolism disorders, particularly aberrant metabolism of fatty acids (FAs) in gastric cancer cells, as well as an upregulation of the expression and activity of key enzymes in lipid metabolism. These changes remind us of the occurrence and development of gastric cancer. These metabolic changes are not unique to cancer cells. Changes in metabolic procedures also determine the function and viability of immune cells. In the immune microenvironment of gastric cancer, the metabolic competition and interaction between cancer cells and immune cells are not very clear, while a deeper understanding of the topic is critical to targeting the differential metabolic requirements of them that comprise an immune response to cancer offers an opportunity to selectively regulate immune cell function. Conclusions: Recent research suggests that targeting metabolism is an emerging and potentially promising treatment strategy for gastric cancer patients. We need to explore it further.